Our database has undergone a major update! We expect some minor teething issues, please let us know by using the Report an issue button at the top of every page if you spot anything that doesn't work.

• 1/6 Recruitment for Cosentyx (secukinumab) and Spevigo (spesolimab) ended on 1 August 2026 - please enter any eligible participants onto the database by 21 August
• 2/6 BADBIR will be attending the BDNG Conference from 13 October 2026 for the full three-day event
• 3/6 Recruitment for patients commencing Sotyktu (deucravicitinib) ended on 20th May 2026
• 4/6 Read more: Changes to conventional cohort eligibility criteria
• 5/6 Our new 2026 Annual Update is now available to read
• 6/6 Patients diagnosed with Generalised Pustular Psoriasis are eligible on Spevigo (spesolimab) or conventional treatment

Find out more on our website.